On Wednesday, H.C. Wainwright reaffirmed its Buy rating and $40.00 stock price target for GH Research PLC (NASDAQ:GHRS), following the company's third-quarter financial results and corporate update. The update included progress on GH Research's lead candidates, GH001 and GH002, which are being developed for various depressive disorders.
GH Research announced the completion of enrollment for its European Phase 2b trial (GH001-TRD-201) of GH001, an inhalable psychedelic compound, in treatment-resistant depression (TRD). The company expects to release top-line data between the fourth quarter of 2024 and the first quarter of 2025.
Moreover, GH Research is on track to finish a six-month open-label extension of the same trial in the first quarter of 2025, which could offer more information on the long-term safety and efficacy of GH001.
The company is also conducting a Phase 1 clinical pharmacology trial in the U.K. (GH001-HV-106) using GH's proprietary aerosol inhalation device. This study aims to bridge the clinical data obtained with a third-party device used in European trials.
Concurrently, non-clinical studies are underway to address the inhalation toxicology concerns raised by the FDA, which could potentially allow GH Research to finalize its response to the agency's clinical hold on the Investigational New Drug (IND) application for GH001.
Further updates include the anticipated completion of a Phase 2a trial evaluating GH001 in postpartum depression (PPD (NASDAQ:PPD)) and a Phase 2 trial in type II bipolar depression (BPII) by the fourth quarter of 2024. The company suggests that top-line data from these trials may be available in the first half of 2025.
H.C. Wainwright's reiteration of the Buy rating and $40 price target reflects the firm's continued confidence in GH Research's potential and the progress of its clinical programs.
In other recent news, GH Research has made significant progress in its clinical trials and leadership changes. The company's third-quarter results for 2024 featured updates on the European Phase 2b trial of GH001, a treatment for treatment-resistant depression. Analysts from Canaccord Genuity maintained its Buy ratings on GH Research, adjusted its price target from $31 to $28.
The company has also announced the appointment of Dr. Velichka Villy Valcheva as its new Chief Executive Officer. Dr. Valcheva brings over two decades of pharmaceutical sector experience to the role, replacing co-founder PD Dr. med. Theis Terwey.
In addition, GH Research is conducting a Phase 1 clinical pharmacology study in the United Kingdom (TADAWUL:4280), supporting the transition to clinical data obtained with GH's proprietary inhalation device.
Another recent development is the company's anticipation of releasing top-line data from its Phase 2a trial for postpartum depression. Moreover, GH Research's Phase 2b trial for GH001 is progressing as planned, with completion of enrollment expected soon. These recent developments underscore GH Research's ongoing commitment to advancing its clinical programs and addressing significant unmet medical needs in the field of depression.
InvestingPro Insights
GH Research's financial and market position offers interesting insights for investors considering the company's potential. According to InvestingPro data, GH Research has a market capitalization of $499.99 million, reflecting its current valuation in the biotech sector. The company's stock has shown strong performance over the past year, with a 55.5% price total return, and an even more impressive 65.69% return year-to-date, indicating growing investor interest in its clinical programs.
InvestingPro Tips highlight that GH Research holds more cash than debt on its balance sheet, which is crucial for a biotech company funding multiple clinical trials. This solid financial footing aligns with the company's ability to continue its research and development efforts, including the ongoing Phase 2b trial for GH001 in treatment-resistant depression.
However, it is important to note that GH Research is not currently profitable, with a negative EBITDA of -$48.4 million over the last twelve months. This is not uncommon for biotech companies in the development stage, and the company's focus on advancing its clinical pipeline, as detailed in the article, explains this financial position.
For investors seeking a deeper understanding of GH Research's potential, InvestingPro offers 8 additional tips that could provide valuable insights into the company's prospects and financial health.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.